NASDAQ:JNP - Juniper Pharmaceuticals Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume28,513 shs
Average Volume155,873 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Juniper Pharmaceuticals, Inc, a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNP
CUSIPN/A
Phone617-639-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive JNP News and Ratings via Email

Sign-up to receive the latest news and ratings for JNP and its competitors with MarketBeat's FREE daily newsletter.

Juniper Pharmaceuticals (NASDAQ:JNP) Frequently Asked Questions

What is Juniper Pharmaceuticals' stock symbol?

Juniper Pharmaceuticals trades on the NASDAQ under the ticker symbol "JNP."

How were Juniper Pharmaceuticals' earnings last quarter?

Juniper Pharmaceuticals Inc (NASDAQ:JNP) announced its earnings results on Thursday, August, 9th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.18. The specialty pharmaceutical company had revenue of $15.31 million for the quarter, compared to analysts' expectations of $16.30 million. View Juniper Pharmaceuticals' Earnings History.

Has Juniper Pharmaceuticals been receiving favorable news coverage?

Press coverage about JNP stock has been trending neutral on Thursday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Juniper Pharmaceuticals earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Juniper Pharmaceuticals.

Who are some of Juniper Pharmaceuticals' key competitors?

What other stocks do shareholders of Juniper Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Juniper Pharmaceuticals investors own include Gilead Sciences (GILD), Novavax (NVAX), Idera Pharmaceuticals (IDRA), Madrigal Pharmaceuticals (MDGL), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Evoke Pharma (EVOK), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

Who are Juniper Pharmaceuticals' key executives?

Juniper Pharmaceuticals' management team includes the folowing people:
  • Ms. Alicia Secor, Pres, CEO & Director (Age 55)
  • Mr. Jeffrey E. Young, CFO, Sr. VP of Fin., Treasurer & Sec. (Age 45)
  • Dr. Nikin Patel, COO & Director (Age 45)
  • Dr. Shen Luk BSc, Ph.D., Chief Scientific Officer
  • Dr. Claire Madden-Smith BSc, Ph.D., Sr. VP of Juniper Pharma Services

What is Juniper Pharmaceuticals' official website?

The official website for Juniper Pharmaceuticals is http://www.juniperpharma.com/.

How can I contact Juniper Pharmaceuticals?

Juniper Pharmaceuticals' mailing address is 33 Arch Street, Boston MA, 02110. The specialty pharmaceutical company can be reached via phone at 617-639-1500 or via email at [email protected]


MarketBeat Community Rating for Juniper Pharmaceuticals (NASDAQ JNP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Juniper Pharmaceuticals and other stocks. Vote "Outperform" if you believe JNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/27/2019 by MarketBeat.com Staff

Featured Article: Treasury Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel